Proceedings of the International scientific and practical conference ― Cambridge Science and Education Conference‖ (February 23-25, 2026) / Publisher website: www.naukainfo.com. – Cambridge, United Kingdom, 2026. - 289 p.

230 p=0.0006), and in the 2nd — 4.34 ± 0.09 mmol/L (+17%; p=0.0017). Therefore, regardless of the specificity of the pathology, non-HDL-C is a reliable and universal marker of lipid metabolism disorders. The level of uric acid in patients with combined pathology (Group 1) equaled 351.56 ± 5.42 µmol/L, which is 26% higher than the control data (278.10 ± 5.26 µmol/L; p=0.0203). In the 2nd group, it was 313.20 ± 6.75 µmol/L (+13%; p≈0.07), and in the 3rd — 328.90 ± 10.63 µmol/L (+18%; p≈0.07). Although the differences in the last two groups were not completely reliable, the upward trend is very clear. This indicates that hyperuricemia acts as an important additional risk factor, which is maximally exacerbated in comorbidity. The concentration of glycated hemoglobin reliably increased only in the 1st group (to 5.95 ± 0.04%, which is 13% higher than the control, p=0.0003). For the 2nd and 3rd groups, these values were 5.49 ± 0.02% and 5.37 ± 0.02%, respectively. This indicates that the destabilization of the glycemic profile is a specific sign precisely of the combination of AH and AS. The HOMA index, reflecting the degree of insulin resistance, reached its maximum in the main group — 2.90 ± 0.07 (this is more than twice the normal 1.39 ± 0.04; p=0.0003). In groups with isolated pathology, it was 1.84 ± 0.06 (Group 2) and 1.56 ± 0.04 (Group 3). Thus, pronounced insulin resistance primarily accompanies comorbid conditions. Summarizing, the most severe metabolic deviations are observed in patients with a combination of AH and AS: the content of Lp(a) increases almost 2-fold, non- HDL-C and uric acid increase by a quarter, HbA1c — by 13%, and HOMA — by more than twice. With isolated AS, the leading position is occupied by high Lp(a), while with isolated AH, metabolic shifts are least pronounced. The control group acted as a reliable guideline for differentiating these pathogenetic features. The data we collected significantly deepen modern understanding of the nature of residual risk in comorbid patients. First of all, our study reinforces the concept according to which non-HDL-C is the most informative integral indicator of atherogenicity, especially against the background of insulin resistance [9, 10]. This is